Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MAXAIR vs AEROLONE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Beta-2 adrenergic receptor agonist; relaxes bronchial smooth muscle via increased intracellular c AMP.
Selective beta2-adrenergic receptor agonist that relaxes bronchial smooth muscle by increasing cyclic AMP production via adenylate cyclase activation.
Prevention and treatment of bronchospasm in patients with reversible obstructive airway disease (e.g., asthma, COPD)
Treatment of bronchospasm in patients with COPD,Long-term maintenance treatment of asthma
2 inhalations (340 mcg) via oral inhalation every 4-6 hours as needed for bronchospasm; not to exceed 12 inhalations per day.
AEROLONE is not a recognized drug; no standard dosing available.
3.5–4.0 hours; clinically, this supports dosing every 4–6 hours as needed.
Terminal elimination half-life is approximately 12-15 hours in adults; prolonged to 24-30 hours in severe renal impairment (Cr Cl <30 m L/min).
Primarily hepatic via glucuronidation and sulfate conjugation; also metabolized by catechol-O-methyltransferase (COMT).
Primarily metabolized by CYP3A4 and to a lesser extent CYP2D6, with conjugation to inactive metabolites.
Renal excretion of unchanged drug accounts for approximately 90% of elimination; fecal excretion is minimal (<5%).
Primarily renal excretion of unchanged drug (approximately 65%) and hepatic metabolism (35%), with metabolites excreted in urine and feces. Biliary/fecal elimination accounts for <10%.
55–70%, primarily to albumin.
Approximately 88% bound, primarily to albumin and alpha-1-acid glycoprotein.
2.0–2.5 L/kg; indicates extensive distribution into tissues.
3.5-5.0 L/kg, indicating extensive extravascular distribution and tissue binding.
Inhalation: approximately 20–30% of the delivered dose reaches the systemic circulation; oral bioavailability is <1% due to first-pass metabolism.
Oral: 35-50% (first-pass metabolism); Inhalation: 15-30% (dependent on device and technique); Intravenous: 100%.
No specific dose adjustment required; medication is primarily hepatically metabolized.
No data; not applicable.
No specific dose adjustment guidelines; use caution in severe hepatic impairment due to potential decreased drug clearance.
No data; not applicable.
Children 6-11 years: 1-2 inhalations (170-340 mcg) via oral inhalation every 4-6 hours as needed; maximum 8 inhalations per day. Children ≥12 years: same as adult.
No data; not applicable.
No specific dose adjustment; monitor for increased sensitivity to beta-agonists (e.g., tachycardia, tremor) and concurrent diseases (e.g., cardiovascular disorders).
No data; not applicable.
No FDA boxed warning.
None
Paradoxical bronchospasm,Cardiovascular effects (tachycardia, arrhythmias, hypertension),Hypokalemia,Hyperglycemia,Immediate hypersensitivity reactions
Paradoxical bronchospasm,Cardiovascular effects (e.g., increased heart rate, QT prolongation),Hypokalemia,Hyperglycemia
Hypersensitivity to pirbuterol or any component,Pre-existing cardiac arrhythmias (e.g., tachyarrhythmias)
Hypersensitivity to arformoterol or any component of the formulation
No specific food interactions. Avoid excessive caffeine intake as it may increase stimulant effects. Grapes, grapefruit, and grapefruit juice have no significant interaction with pirbuterol.
No significant food interactions. Avoid grapefruit juice as it may affect metabolism of the corticosteroid component.
FDA Pregnancy Category C. No adequate and well-controlled studies in pregnant women. In animal studies, maxair (pirbuterol) showed no teratogenic effects at doses up to 20 mg/kg/day in rats and up to 10 mg/kg/day in rabbits, but fetal growth retardation and increased mortality were observed at maternally toxic doses. Risk to human fetus cannot be ruled out. Use during pregnancy only if potential benefit justifies potential risk.
No evidence of teratogenicity in animal studies at doses up to 10 mg/kg/day (approximately 120 times the maximum recommended human daily inhaled dose). In humans, no controlled studies exist; however, data from postmarketing reports do not suggest an increased risk of structural anomalies. First trimester: limited data preclude definitive risk assessment, but no pattern of major birth defects has emerged. Second and third trimesters: no known fetal harm from inhaled doses; however, potential for fetal adrenal suppression with prolonged high-dose systemic exposure.
Unknown if pirbuterol is excreted in human milk. Due to lack of data and potential for serious adverse reactions in nursing infants, caution is advised. M/P ratio not determined.
Unknown whether fluticasone propionate is excreted in human breast milk. Other corticosteroids are excreted in breast milk in low amounts, and inhaled doses result in negligible systemic levels, predicting unlikely significant infant exposure. M/P ratio not determined. Caution advised; weigh risk of maternal obstructive airway disease exacerbation against potential infant risks (adrenal suppression, growth retardation).
No specific pharmacokinetic data in pregnancy; standard dosing recommended. Beta-agonists may delay preterm labor; use with caution.
No specific dose adjustment required based on pharmacokinetic changes; pregnancy may cause decreased airway reactivity but no significant changes in fluticasone clearance. Maintain lowest effective dose to control asthma. No dose increase recommended solely due to pregnancy. Monitor asthma control and adjust dose as per standard guidelines.
MAXAIR (pirbuterol) is a beta-2 adrenergic agonist for asthma and COPD. Use with caution in patients with cardiovascular disorders, especially coronary insufficiency, arrhythmias, or hypertension. Monitor for paradoxical bronchospasm; if occurs, discontinue immediately. Not indicated for acute severe asthma exacerbations unless patient is closely monitored. Can cause hypokalemia, especially with concomitant use of corticosteroids or diuretics. Administer with a spacer device to improve lung deposition and reduce oral side effects.
AEROLONE is a combination inhaler containing an inhaled corticosteroid (fluticasone propionate) and a long-acting beta2-agonist (salmeterol). Advise patients to rinse mouth with water after each use to reduce risk of oral candidiasis. Not for acute bronchospasm; use a rescue inhaler (short-acting beta agonist) as needed. Monitor for increased heart rate, palpitations, or tremor. Do not stop abruptly; taper dose under medical supervision if discontinuing.
Use only as prescribed; do not exceed recommended doses.,Rinse mouth after inhalation to prevent oral thrush.,Contact doctor if symptoms worsen or if you need more than usual doses.,Do not share the inhaler; keep it clean.,Seek immediate medical help if you experience chest pain, rapid heartbeat, or severe wheezing after use.,Inform your doctor if you have heart disease, high blood pressure, seizures, or diabetes.,Avoid using with other asthma medications without consulting your doctor.
Use AEROLONE exactly as prescribed; do not exceed recommended dose.,Rinse your mouth with water after each use (do not swallow) to prevent thrush.,This medication is not for sudden breathing problems; always keep your rescue inhaler (e.g., albuterol) with you.,Do not stop using this medicine without talking to your doctor, as stopping suddenly may worsen your breathing.,Seek immediate medical help if you experience worsening asthma, chest pain, or allergic reaction.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MAXAIR vs AEROLONE, answered by our medical review team.
MAXAIR is a Bronchodilator that works by Beta-2 adrenergic receptor agonist; relaxes bronchial smooth muscle via increased intracellular c AMP.. AEROLONE is a Bronchodilator that works by Selective beta2-adrenergic receptor agonist that relaxes bronchial smooth muscle by increasing cyclic AMP production via adenylate cyclase activation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MAXAIR and AEROLONE depend on the specific clinical indication. These are both Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MAXAIR is: 2 inhalations (340 mcg) via oral inhalation every 4-6 hours as needed for bronchospasm; not to exceed 12 inhalations per day.. The standard adult dose of AEROLONE is: AEROLONE is not a recognized drug; no standard dosing available.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MAXAIR and AEROLONE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MAXAIR is classified as Category C. FDA Pregnancy Category C. No adequate and well-controlled studies in pregnant women. In animal studies, maxair (pirbuterol) showed no teratogenic effects at doses up to 20 mg/kg/da. AEROLONE is classified as Category C. No evidence of teratogenicity in animal studies at doses up to 10 mg/kg/day (approximately 120 times the maximum recommended human daily inhaled dose). In humans, no controlled stu. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.